Regenerative Medicine
Nanomaterials for tissue engineering and regenerative therapies
Selecta Biosciences
Watertown, United States
Selecta Biosciences, Inc., founded in 2007 and based in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company developing its proprietary ImmTOR nanoparticle platform to address a critical challenge in biologics therapy—unwanted immune responses that reduce treatment efficacy. Publicly traded on NASDAQ (SELB) with over $300 million in funding and 100-200 employees, Selecta has pioneered synthetic vaccine particles (SVP) that can selectively modulate immune responses, potentially enabling repeat administration of therapeutic proteins and gene therapies. The company emerged from research on how nanoparticle properties influence immune system activation, discovering that specific nanoparticle designs could induce immune tolerance rather than immunogenicity. Selecta's ImmTOR platform consists of biodegradable polymer nanoparticles incorporating immunomodulatory small molecules (typically rapamycin analogs) that are taken up by immune cells, inducing tolerance to co-administered therapeutic agents. This approach addresses a major limitation of protein therapeutics and gene therapies—the development of neutralizing antibodies that reduce or eliminate treatment efficacy with repeated dosing. For example, many patients with gout receiving enzyme replacement therapy develop anti-drug antibodies that neutralize the therapeutic enzyme, requiring treatment discontinuation. Selecta's lead program, SEL-212, combines ImmTOR nanoparticles with pegsiticase enzyme therapy for severe gout, with clinical trials demonstrating reduced immunogenicity and improved sustained therapeutic response. The company has expanded its platform to address immunogenicity challenges in gene therapy, where immune responses against viral vectors or therapeutic proteins can limit treatment durability. Selecta has established partnerships with major pharmaceutical companies including Sarepta Therapeutics and Asklepios BioPharmaceutical to apply ImmTOR technology to gene therapy programs for muscular dystrophies and other genetic diseases. The company's nanoparticles are engineered with precise sizes (typically 200-500 nanometers), controlled drug loading, and surface properties optimized for uptake by specific immune cell populations. Selecta has developed manufacturing processes producing clinical-grade ImmTOR nanoparticles at scales required for therapeutic applications, addressing a key challenge in nanomedicine translation. The company's approach represents sophisticated application of nanotechnology principles—using nanoparticle properties to program specific biological responses rather than simply delivering drugs. Selecta's clinical programs have generated important data on how synthetic nanoparticles can modulate human immune systems, contributing to fundamental understanding of nanoparticle immunology. As gene therapies and protein biologics become increasingly important in medicine, addressing immunogenicity challenges will be crucial for enabling repeat dosing and expanding patient populations. Selecta's ImmTOR platform offers a potentially broadly applicable solution to this critical problem, positioning the company at the intersection of nanomedicine and immunotherapy, two of the most promising areas in biopharmaceutical development.
Nanofiber Solutions
Columbus, United States
Developer of 3D nanofiber scaffolds for tissue engineering and cell culture applications
NanoViricides
Shelton, United States
Developer of nanoviricide drugs designed to attack and destroy viruses
NanoMedical Systems
Austin, United States
Developer of nanochannel drug delivery implants for sustained therapeutic release
Arch Venture Partners
Chicago, United States
Venture capital firm focusing on early-stage technology companies including nanotech
Nanobiotix SA
Cambridge, United States
Clinical-stage nanomedicine company developing first-in-class radioenhancers using hafnium oxide nanoparticles
NanoMedSyn
Montpellier, France
Developer of MUSIC nanoparticle platform for targeted drug delivery
Nanovis
West Lafayette, United States
Developer of nanotube-reinforced polymer implants for orthopedic applications
NanoMed
Lancaster, United States
Developer of nanoscale surgical instruments
NanoPass Technologies
Ness Ziona, Israel
Developer of microneedle drug delivery systems
SciSparc
Tel Aviv, Israel
Nano-drug delivery for CNS disorders
BioDynamics Laboratory
Tokyo, Japan
Nanogel and polymer technology for drug delivery applications
NanoBio Corporation
Ann Arbor, United States
Nanoemulsion technology for intranasal vaccines and skin treatments
Ceramisphere
Sydney, Australia
Ceramic nanoparticle drug delivery systems
Camurus
Lund, Sweden
FluidCrystal lipid-based drug delivery systems
Takeda Pharmaceutical
Tokyo, Japan
Global pharma with nanomedicine programs
Astellas Pharma
Tokyo, Japan
Major pharma with nanotechnology drug delivery research
Daiichi Sankyo
Tokyo, Japan
Antibody-drug conjugates and nanomedicine oncology
Eisai Co.
Tokyo, Japan
Neurology and oncology with nanoformulation research
Otsuka Pharmaceutical
Tokyo, Japan
CNS and oncology pharma with nanomedicine development
Sumitomo Pharma
Osaka, Japan
Regenerative medicine and nanomedicine programs
Chugai Pharmaceutical
Tokyo, Japan
Antibody engineering and innovative drug delivery
Hanmi Pharmaceutical
Seoul, South Korea
LAPSCOVERY long-acting drug delivery platform
Yuhan Corporation
Seoul, South Korea
Korean pharma with nanoformulation programs
Daewoong Pharmaceutical
Seoul, South Korea
Innovative drug delivery and biologics
Hengrui Medicine
Lianyungang, China
Leading Chinese pharma with nanomedicine oncology programs
CSPC Pharmaceutical
Shijiazhuang, China
Major Chinese pharma with nanomedicine research
Hansoh Pharmaceutical
Lianyungang, China
Innovative Chinese pharma with nanoformulation expertise
Zhejiang Medicine
Shaoxing, China
API manufacturer with nano-formulation capabilities
Luye Pharma Group
Yantai, China
Advanced drug delivery including microspheres and liposomes
Taiwan Liposome Company
Taipei, Taiwan
BioSeizer and NanoX liposomal drug delivery platforms
PharmaEngine
Taipei, Taiwan
Liposomal formulations for cancer treatment
Celsion Corporation
Lawrenceville, United States
ThermoDox heat-activated liposomal doxorubicin
Medtronic
Dublin, Ireland
Medical device company with nanotechnology applications in implants and drug delivery
Boston Scientific
Marlborough, United States
Medical devices with nano-coated drug-eluting stents and implants
Stryker
Kalamazoo, United States
Orthopedic implants with nanostructured surfaces for improved osseointegration
Zimmer Biomet
Warsaw, United States
Orthopedic devices with nanotextured implant surfaces and 3D-printed structures
Smith+Nephew
Watford, United Kingdom
Medical devices with nanocrystalline silver wound care and orthopedic implants
Edwards Lifesciences
Irvine, United States
Heart valve technologies with nano-engineered surfaces and coatings
Abbott Vascular
Santa Clara, United States
Cardiovascular devices with drug-eluting nano-coated stents
Selecta Biosciences
Watertown, United States
ImmTOR biodegradable nanoparticles for immune tolerance induction
NanOlogy
Fort Worth, United States
Submicron particle technology for localized drug delivery in cancer treatment
Halozyme Therapeutics
San Diego, United States
ENHANZE technology enabling subcutaneous delivery of biologics
Bharat Biotech
Hyderabad, India
Vaccine developer with nanoparticle-based vaccine platforms
NOF Corporation
Tokyo, Japan
PEG-lipid conjugates and functional lipids for liposome drug delivery
University College London Nano
London, United Kingdom
Major UK university with London Centre for Nanotechnology
Denali Therapeutics
South San Francisco, United States
Neurodegeneration drugs using Transport Vehicle BBB-crossing technology
Voyager Therapeutics
Cambridge, United States
AAV capsid engineering for CNS gene therapy delivery
4D Molecular Therapeutics
Emeryville, United States
Therapeutic vectors using Directed Evolution AAV capsid discovery
Bluebird Bio
Somerville, United States
Gene therapy using lentiviral vectors for genetic diseases
Bicycle Therapeutics
Cambridge, United Kingdom
Bicyclic peptide platform for targeted drug delivery
Bioasis Technologies
Guilford, Canada
xB3 platform for blood-brain barrier crossing drug delivery
Annexon Biosciences
Brisbane, United States
Complement cascade inhibitors for neurological diseases
Prevail Therapeutics
New York, United States
Gene therapies for neurodegenerative diseases (Eli Lilly)
Applied Genetic Technologies
Alachua, United States
AAV gene therapies for rare ophthalmologic diseases
Krystal Biotech
Pittsburgh, United States
Gene therapies using HSV-1 vectors for skin diseases
Solid Biosciences
Charlestown, United States
Gene therapy for Duchenne muscular dystrophy
Ultragenyx Pharmaceutical
Novato, United States
Gene therapy and biologics for rare genetic diseases
Genethon
Evry, France
Non-profit gene therapy research laboratory
Orchard Therapeutics
London, United Kingdom
Hematopoietic stem cell gene therapy for rare diseases
Cellectis
Paris, France
TALEN gene editing for allogeneic CAR-T cell therapy
Carisma Therapeutics
Philadelphia, United States
CAR-Macrophage therapy for solid tumors
Fate Therapeutics
San Diego, United States
iPSC-derived cell therapies including NK and T cells
Organovo
San Diego, United States
3D bioprinting pioneer developing human tissues for drug discovery and therapeutic applications
Aspect Biosystems
Vancouver, Canada
Microfluidic bioprinting for tissue therapeutics and drug delivery applications
Prellis Biologics
San Francisco, United States
Holographic bioprinting for vascularized tissues and organs at high speed and resolution
Stryker Robotics
Kalamazoo, United States
Medical technology company with Mako robotic-arm assisted surgery system
Rewalk Robotics
Yokneam, Israel
Wearable robotic exoskeletons enabling individuals with spinal cord injury to walk
Ekso Bionics
Richmond, United States
Exoskeleton technology for medical rehabilitation and industrial applications
Ultragenyx Pharmaceutical
Novato, United States
Biopharmaceutical company developing novel products for rare and ultra-rare diseases
Allogene Therapeutics
South San Francisco, United States
Clinical-stage biotechnology company pioneering allogeneic CAR T cell therapies
Adicet Bio
Menlo Park, United States
Clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies
Century Therapeutics
Philadelphia, United States
Biotechnology company developing iPSC-derived allogeneic cell therapies for cancer
Daiichi Sankyo ADC
Tokyo, Japan
Global pharmaceutical company with leading ADC technology platform
WuXi Advanced Therapies
Shanghai, China
Global contract development and manufacturing organization for advanced therapies
Asklepios BioPharmaceutical
Research Triangle Park, United States
Gene therapy company developing AAV-based treatments for genetic diseases
Neurogene
New York, United States
Gene therapy company developing treatments for rare neurological diseases in children
Taysha Gene Therapies
Dallas, United States
Gene therapy company developing treatments for monogenic CNS diseases
Nevro
Redwood City, United States
Medical device company developing high-frequency spinal cord stimulation therapy
Axonics
Irvine, United States
Medical technology company developing rechargeable sacral neuromodulation systems
LivaNova
London, United Kingdom
Medical technology company focused on neuromodulation and cardiopulmonary
NeuroPace
Mountain View, United States
Medical device company developing responsive neurostimulation for epilepsy
Penumbra
Alameda, United States
Medical device company developing innovative therapies for vascular conditions
ABIOMED
Danvers, United States
Medical device company developing heart recovery technologies
Inspire Medical Systems
Maple Grove, United States
Medical technology company developing implantable neurostimulation for sleep apnea
TransMedics
Andover, United States
Medical technology company developing organ care system for transplantation
NuVasive
San Diego, United States
Medical device company developing spine surgery solutions
Globus Medical
Audubon, United States
Medical device company developing musculoskeletal solutions and robotics
Integra LifeSciences
Princeton, United States
Global medical technology company focused on regenerative technologies
AngioDynamics
Latham, United States
Medical device company developing minimally invasive medical devices
Therabody
Los Angeles, United States
Wellness technology company known for Theragun percussion devices
pSivida (Eyepoint)
Watertown, United States
Sustained ocular drug delivery
Nanotope
Evanston, United States
Self-assembling peptide nanomaterials
Nanopass Technologies
Ness Ziona, Israel
Microneedle technology for intradermal drug delivery
Theranautilus
Bangalore, India
Nanobots for dental healthcare and root canal disinfection
Nanobiotec
Madrid, Spain
Nanomedicine and drug delivery solutions
iCeutica
Sydney, Australia
Encapsulated Organic Nanoparticles (EON) platform for nano-sized drug particles
Meda Biotech
Shanghai, China
Hybrid-nanoengineered water soluble drugs optimizing drug trafficking to disease sites
Revalesio Corporation
Tacoma, United States
Oxygen delivery technology at nano-scale for therapeutic applications
Adocia
Lyon, France
BioChaperone nanoformulation technology for improved insulin delivery
Nanocare
Mumbai, India
Silver nanoparticle antimicrobial coatings for textiles and medical applications
HK Inno.N
Seoul, South Korea
Pharmaceutical nanotechnology for drug delivery systems
Ceramat
Chennai, India
Nano-hydroxyapatite ceramic implant coatings and bone grafting materials
Promimic
Gothenburg, Sweden
HAnano Surface hydroxyapatite coating for dental and orthopedic implants
SofSera
Tokyo, Japan
Hydroxyapatite nanoparticles for dental and biomedical applications
Inosep
Seoul, South Korea
Polymer nanofiltration membranes for water treatment and desalination
Aruna Bio
Athens, United States
Neural-derived exosomes for CNS drug delivery crossing BBB
Nanordica Medical
Tartu, Estonia
Silver and copper nanoparticle wound care products
ConvaTec Aquacel
Reading, United Kingdom
Aquacel silver-based wound care technology